Reference scaled ABE - FDA [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2010-04-27 10:58 (5907 d 05:55 ago) – Posting: # 5243
Views: 41,989

Hi Dave,

wow! Very valuable contribution! :clap:

Fascinating: The codes provided rely solely on suitably choosen intra-subject contrasts! Sometimes called Method of Moments if I'm not wrong. No explicit mixed effects modeling(!) with the exception of the "conventional" unscaled ABE analysis for a fully (4-period) replicate design.

BTW: What is missing is explicit code for ABE evaluation for the partial replicate design in case of sWR < 0.294 (CV = 30%): "The two one-sided test procedure must be used for PK parameters with sWR < 0.294."

BTW2: It is not clear why they recommend Proc MIXED in case of fully replicate design and Proc GLM in case of partial replicate. In both cases the call to these procedures have only sequence as fixed effect. They only serve as means to get the sequence "stratified" means of the corresponding inter-subject contrasts. Or is this meant with respect to the unscaled ABE evaluation?

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
181 visitors (0 registered, 181 guests [including 15 identified bots]).
Forum time: 16:53 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5